Cheryl Guttman Krader, BS, Pharm

A logistic regression analysis controlling for other major comorbidities, patient age, insurance status, and type of medical therapy found that Black patients were almost 40% less likely than White patients to undergo surgery for BPH.

A crude logistic regression analysis showed that adjunctive pharmacotherapy did not significantly change the odds of improving nocturia severity.

"Early data suggest that low testosterone levels increase the risk of developing severe disease and that testosterone supplementation may provide benefit for men who are infected by the SARS-CoV-2 virus," says Mohit Khera, MD, MBA, MPH.

“With 18F-DCFPyL-PET/CT, we can find metastatic disease much sooner. Therefore, 1 question that will need to be addressed is: what do we do now?” says Kenneth J. Pienta, MD.

Amplitude setting as low as 50% below sensory level is effective for treating overactive bladder.

The study also confirms the growing popularity of ureteroscopy as a stone management tool.

The device can now be marketed throughout the EU, as well as in Iceland, Liechtenstein, and Norway.

Review of nearly 5600 patients found a 5% pooled incidence of postoperative urosepsis.

Odds of having UI were 56% higher in women with vs women without diabetes.

Depression appears to be common in patients, retrospective data indicate.

Findings support the modality’s use in biochemically recurrent prostate cancer, investigator says.

North American urologists analyzing outcomes from their initial experience treating urolithiasis with the high-power super pulse thulium fiber laser (Soltive) are encouraged by the results.

“The 2-year results are very impressive and underline what SNM can offer to patients with UUI," said Andrea M. Pezzella, MD.

"Our study demonstrates the feasibility of HIVEC MMC and suggests it is a reasonable substitute for BCG during global shortages," says urologist Scott P. Campbell, MD.

The rechargeable implantable neurostimulator is approved for the treatment of patients with urinary and bladder dysfunction.

Analyses of data collected in a prospectively maintained database support the recommendation for urologists to consider the minimally invasive version of mini-percutaneous nephrolithotomy for stone removal in patients with medium-sized stones (10-20 mm).

Acute urinary retention is not uncommon among men who undergo placement of a proprietary transobturator sling (AdVance) for management of postprostatectomy SUI. Still, it is rarely persistent, according to a recent study.

Lobe enucleation efficiency is significantly better with Moses technology, investigators report.

Because of the limitations of the research, the findings need to be considered with caution, said Lourdes Guerrios-Rivera, MD, MSc.

The paper is meant to serve as a single source of information for helping patients with bladder cancer.

Next-generation DNA sequencing can identify more than 50,000 microorganisms.

Short-term outcomes suggest feasibility of active surveillance for men carrying germline DNA repair gene mutations.

Investigators have developed a cloud-based, HIPAA–compliant software solution to ensure timely ureteral stent removal and validated its performance in a pilot study.

Men who receive care for erectile dysfunction from their primary care provider are much less likely to receive advanced pharmacological therapies for management of their condition than those treated by urologists.

Based on the findings, investigators recommended that systematic biopsy be performed in patients with negative MRI and in addition to targeted biopsies in men with a positive MRI.

Tele-cystoscopy was found equivalent to traditional cystoscopy with respect to identification of abnormalities and action decisions.

Feasibility study results indicate the nonimplanted, intravaginal device is safe and comfortable.

Super-pulsed thulium fiber laser (TFL) has greater efficiency than a holmium:YAG laser, even when using the TFL with a smaller core-diameter fiber, according to preclinical findings.

The machine learning algorithm incorporates readily available clinical information.

Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.